Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
36°
Mostly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Veracyte, Inc.
< Previous
1
2
3
4
5
Next >
Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia
November 05, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
November 03, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities
November 02, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Data Demonstrate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery
October 26, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer
October 25, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
October 14, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Publication Demonstrates Ability of Veracyte’s Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy
October 13, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021
October 12, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis
October 11, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test’s Ability to Improve Early Lung Cancer Assessment
October 11, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte’s Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease
October 06, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy
September 14, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology
September 01, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
August 31, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year
August 23, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces Second Quarter 2021 Financial Results
July 29, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer
July 27, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth
July 12, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021
July 08, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion
July 08, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team
July 01, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer
June 14, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder
June 04, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
CORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences
June 02, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte to Present at Upcoming Investor Conferences
June 02, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth
June 01, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA Samples
May 26, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic Classifier
May 25, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection
May 19, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte to Present at Upcoming Investor Conferences
May 18, 2021
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.